Horizon Therapeutics (NASDAQ:HZNP) has initiated
PROspective sTudy of pEglotiCase in Transplant patients (PROTECT), an
open-label trial evaluating the use of KRYSTEXXA (pegloticase injection)
in 20 adults with chronic gout refractory to conventional
therapies, also known as uncontrolled gout who have undergone a kidney
transplant.
The study’s primary endpoint is response rate, as
measured by sustained serum uric acid reduction to <6 mg/dL at Month 6
of treatment.
It will also evaluate secondary outcomes such as
complete resolution of at least one tophus, and scores related to pain
and disability.
https://seekingalpha.com/news/3506485-horizon-therapeutics-launches-protect-trial-evaluating-krystexxa-uncontrolled-gout
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.